Related Experiment Videos
Dihydroergotamine suppositories in a headache clinic
Headache
|July 1, 1991
Summary
Dihydroergotamine (DHE) suppositories show promise for treating specific migraine types. This preliminary study suggests DHE suppositories may be a viable option for patients with catamenial and classic migraines.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parenteral dihydroergotamine (DHE) is an established migraine treatment in the US.
- Limited data exists on alternative DHE delivery methods.
Purpose of the Study:
- To evaluate the preliminary efficacy of dihydroergotamine (DHE) suppositories.
- To assess DHE suppositories as a potential treatment for specific migraine subtypes.
Main Methods:
- A preliminary clinical trial was conducted.
- Dihydroergotamine (DHE) suppositories were administered in an outpatient headache clinic setting.
Main Results:
- Dihydroergotamine (DHE) suppositories demonstrated potential utility.
- The treatment may be suitable for patients experiencing catamenial migraine and classic migraine.
Conclusions:
- Dihydroergotamine (DHE) suppositories represent a potentially effective formulation for migraine management.
- Further investigation is warranted for patients with catamenial and classic migraine.